DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms by David J. Lemler et al.
RESEARCH ARTICLE Open Access
DCYTB is a predictor of outcome in breast
cancer that functions via iron-independent
mechanisms
David J. Lemler1,6, Miranda L. Lynch2,7, Lia Tesfay1, Zhiyong Deng1, Bibbin T. Paul1, Xiaohong Wang3,
Poornima Hegde3, David H. Manz1,4, Suzy V. Torti1* and Frank M. Torti5
Abstract
Background: Duodenal cytochrome b (DCYTB) is a ferrireductase that functions together with divalent metal
transporter 1 (DMT1) to mediate dietary iron reduction and uptake in the duodenum. DCYTB is also a member of a
16-gene iron regulatory gene signature (IRGS) that predicts metastasis-free survival in breast cancer patients. To
better understand the relationship between DCYTB and breast cancer, we explored in detail the prognostic
significance and molecular function of DCYTB in breast cancer.
Methods: The prognostic significance of DCYTB expression was evaluated using publicly available microarray data.
Signaling Pathway Impact Analysis (SPIA) of microarray data was used to identify potential novel functions of
DCYTB. The role of DCYTB was assessed using immunohistochemistry and measurements of iron uptake, iron
metabolism, and FAK signaling.
Results: High DCYTB expression was associated with prolonged survival in two large independent cohorts,
together totaling 1610 patients (cohort #1, p = 1.6e-11, n = 741; cohort #2, p = 1.2e-05, n = 869; log-rank test) as
well as in the Gene expression-based Outcome for Breast cancer Online (GOBO) cohort (p < 1.0e-05, n = 1379). High
DCYTB expression was also associated with increased survival in homogeneously treated groups of patients who
received either tamoxifen or chemotherapy. Immunohistochemistry revealed that DCYTB is localized on the
plasma membrane of breast epithelial cells, and that expression is dramatically reduced in high-grade tumors.
Surprisingly, neither overexpression nor knockdown of DCYTB affected levels of ferritin H, transferrin receptor,
labile iron or total cellular iron in breast cancer cells. Because SPIA pathway analysis of patient microarray data
revealed an association between DCYTB and the focal adhesion pathway, we examined the influence of DCYTB
on FAK activation in breast cancer cells. These experiments reveal that DCYTB reduces adhesion and activation of
focal adhesion kinase (FAK) and its adapter protein paxillin.
Conclusions: DCYTB is an important predictor of outcome and is associated with response to therapy in breast
cancer patients. DCYTB does not affect intracellular iron in breast cancer cells. Instead, DCYTB may retard cancer
progression by reducing activation of FAK, a kinase that plays a central role in tumor cell adhesion and
metastasis.
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Background
Iron has been implicated in both the initiation and pro-
gression of cancer. Due to its ability to catalyze the for-
mation of oxygen free radicals, iron can facilitate DNA
damage and lead to potentially mutagenic changes in
DNA [1]. Iron can also act as a tumor growth factor, po-
tentiating the growth of numerous tumors, including
breast tumors, in animal models [2, 3]. Consistent with
these laboratory studies, epidemiologic studies have
linked excess iron and cancer [4–7]. For example, sub-
jects with increased levels of circulating iron are at in-
creased risk of cancer [8–10], and conversely, subjects
who have undergone phlebotomy for iron reduction are
at decreased cancer risk [7].
The major mechanism of iron import in both normal
and malignant cells is the transferrin/transferrin receptor
endocytic pathway. Two molecules of ferric iron bound to
transferrin are endocytosed upon transferrin receptor bind-
ing. Iron is released in the acidified endosome, reduced,
and imported into the cytosol, where it enters a low mo-
lecular weight, metabolically active labile iron pool (LIP).
Excess iron in the cytosol is stored in ferritin or exported
via the iron exporter, ferroportin [11]. Other mechanisms
of iron import include uptake of heme, ferritin, and import
of siderophore-bound iron by proteins such as the secreted
glycoprotein Lipocalin 2 (LCN2, NGAL), [12–15].
In the duodenum, where uptake of dietary iron occurs,
the mechanism of iron import involves duodenal cyto-
chrome b (DCYTB) [16–18]. Dietary iron is largely
present in an oxidized form (ferric iron, Fe+3). DCYTB
acts as a ferrireductase, reducing ferric iron to ferrous
iron to permit iron uptake by divalent metal transporter
1 (DMT1). Identified in 2001 [16], DCYTB is a member
of the cytochrome b561 protein family of di-heme,
transplasma membrane electron transporters [19, 20].
Reduction of iron by DCYTB is pH-dependent and
ascorbate-dependent in duodenal enterocytes [16–18,
21], but ascorbate-independent in bronchial epithelial
cells [22]. Copper is also a substrate for reduction by
DCYTB, a reaction that occurs in a pH-independent,
ascorbate-dependent manner [18]. Additionally, DCYTB
expression has been shown to maintain extracellular
levels of ascorbate [23].
Cancer cells exhibit an enhanced requirement for iron
compared to their normal counterparts. To meet the in-
creased metabolic demand for iron, breast and other
cancer cells frequently increase expression of the iron
importer transferrin receptor [24–26]. Alternatively or
additionally, cancer cells suppress expression of the iron
efflux protein ferroportin [27]. Although retained iron is
sequestered in ferritin, this nevertheless results in an in-
crease in labile iron [27–29].
Measurements of the expression of genes of iron me-
tabolism are strong predictors of patient prognosis. For
example, breast cancer patient microarray data demon-
strate that increased transferrin receptor expression
[30–32] or decreased ferroportin expression in breast tu-
mors are associated with poor prognosis [27]. Tumoral
expression of LCN2 is also associated with poor progno-
sis and increased metastasis in breast cancer [33, 34].
To ascertain which components of iron metabolism
most influence breast cancer prognosis, our group stud-
ied the association of 61 “iron” genes with breast cancer
patient outcome [32]. From these analyses, an “iron gene
regulatory signature” was derived, consisting of 16 genes
whose expression best predicted breast cancer patient out-
come. Of these 16 genes, expression of duodenal cyto-
chrome b (DCYTB, CYBRD1, CYB561A2) was the most
significantly associated with distant metastasis-free survival
(DMFS), with high expression (values above the mean) as-
sociated with a reduced hazard ratio of 0.6 (p = 1.8e-07).
Since DCYTB facilitates iron import, its association with
improved outcome was surprising. The expression of this
gene in the breast was also unanticipated, since its best-
known function involves uptake of dietary iron.
We therefore sought to understand in greater depth
the nature of the association of DCYTB with breast can-
cer, and to explore the role of DCYTB in the breast. We
first expanded our assessment of the ability of DCYTB
to predict patient survival and response to therapy utiliz-
ing large, independent gene expression datasets obtained
from breast cancer patients. We then investigated
whether DCYTB expression influenced iron homeostasis
in malignant breast cells. Our results indicate that
DCYTB expression is strikingly associated with patient
outcome and response to therapy. However, we found
that DCYTB does not affect intracellular iron in breast
cancer cells. Rather, DCYTB inhibits FAK activation and
cell adhesion. These results uncouple DCYTB from iron
metabolism in breast cancer tissue and provide an
explanation for the paradoxical association between in-
creased DCYTB expression and favorable prognosis in
breast cancer patients.
Results
DCYTB as a prognostic indicator of breast cancer
Expression of DCYTB predicts metastasis/relapse-free
survival
We first examined the prognostic significance of DCYTB
when considered as a single gene rather than as part of the
larger IRGS gene signature [32]. Analysis of the combined
cohort of 741 breast cancer patients that was used in the
design of the IRGS [32] (herein termed cohort #1), revealed
that high DCYTB expression (values above the mean) was
an excellent overall predictor of distant metastasis-free
survival (p = 1.6e-11, n = 741, log-rank test; Fig. 1a).
We then validated and expanded our results using
additional datasets not included in cohort #1, which we
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combined into a new cohort of 869 patients (cohort #2;
see “Methods”). To construct this cohort, we selected all
larger datasets (n > 100) with sufficient events to mean-
ingfully separate patients by outcome (Table 1). Datasets
that did not meet these criteria (e.g., GSE19615 [35],
TCGA) were excluded. In cohort #2, DCYTB expression
above the mean was again dramatically associated with
increased relapse-free survival (RFS) (p = 1.2e-05, n =
869; log-rank test; Fig. 1b). One of the datasets used to
construct cohort #2 contained information on bone-
specific RFS; analysis of this subgroup (n = 272) further
revealed that DCYTB expression was associated with
bone-specific RFS (Fig. 1c). Consistent with the associ-
ation of high DCYTB with favorable prognosis, we fur-
ther observed that expression of DCYTB was higher in
tumors that expressed estrogen receptor (ER+) than in
ER- tumors (Additional file 1: Figure S1). Additionally,
DCYTB expression decreased with increased tumor
grade (Additional file 1: Figure S2).
We used the gene expression-based outcome for breast
cancer online database (GOBO [36]) to assess the effects
of DCYTB expression in another large combined cohort.
Analysis of this dataset similarly indicates that high
DCYTB expression is associated with increased DMFS
(p < 0.00001, n = 1379, Additional file 1: Figure S3a).
We next tested whether DCYTB expression was
predictive in both estrogen receptor-positive (ER+) and
ER- cohorts. Kaplan-Meier survival analysis of cohort #1
indicated that DCYTB significantly predicted DMFS in-
dependently of estrogen receptor status (p = 1.3e-10 and
p = 0.03, log-rank test, Fig. 2a,b). Similarly, analysis of
cohort #2 revealed that high DCYTB expression was as-
sociated with increased relapse-free survival of both ER+
and ER- patients (p = 0.004 and p = 0.01, log-rank test,
Additional file 1: Figure S4a,b).
We also tested whether DCYTB distinguished out-
come in patients whose disease remained confined to
the breast (LN-) and patients whose disease had spread
to adjacent lymph nodes (LN+). In cohort #1, DCYTB
expression predicted DMFS in both LN+ and LN- pa-
tients (p ≤ 0.0001, log-rank test Fig. 2c,d). The associ-
ation of elevated DCYTB expression with prolonged
relapse-free survival was also observed in LN+ and LN-
patients of cohort #2 (p = 0.02 and p = 0.0001, log-rank
test, Additional file 1: Figure S4c,d).
Multivariate analysis of all patients in cohorts #1
and #2 was then used to determine whether DCYTB
was an independent predictor of outcome. When
characteristics of patients’ primary tumors (i.e. ER sta-
tus, size, and grade) were considered in a multivariate
Cox proportional hazards analysis, DCYTB remained
an independent predictor of outcome (p = 0.03, n =
612, Cox PH, Table 2). Thus DCYTB is an independ-
ent predictor of outcome in patients whose disease
remains confined to the breast. The presence of dis-
ease in adjacent lymph nodes (LN status) is an indi-
cator of propensity to metastatic dissemination. In
this combined cohort, DCYTB expression was not in-




Fig. 1 High DCYTB expression is associated with increased
recurrence-free survival in breast cancer. Kaplan-Meier analysis of
breast cancer patient microarray data subsetted into high and low
DCYTB expression groups (above and below the mean). a Cohort #1
distant metastasis-free survival (p = 1.6e-11, n = 741, log-rank test); b
cohort #2 relapse-free survival (both local and distant) (p = 1.2e-05,
n = 869, log-rank test); c subgroup of cohort #2 (GSE2034) bone-
specific relapse-free survival (p = 0.01, n = 272, log-rank test). DCYTB
duodenal cytochrome b
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in the model (p = 0.25, n = 424, Cox PH, Table 2),
suggesting that DCYTB expression and LN status
may convey somewhat overlapping information – i.e.,
a propensity toward disease dissemination. In con-
trast, in the larger GOBO dataset, DCYTB remained
an independent predictor of outcome when all
variables, including LN status, were included in the
model (p = 0.01, n = 571, Additional file 1: Figure S3b). In
aggregate, these results indicate that high DCYTB expres-
sion is associated with a more favorable prognosis in
breast cancer patients.
DCYTB expression correlates with the better prognosis
breast cancer molecular subtypes
We then investigated the expression of DCYTB within
breast cancer intrinsic molecular subtypes. These subtypes
can be used to divide patients into prognostic subgroups
based on gene expression profiles [37, 38]. When cohort
#1 was divided into intrinsic subtypes, the expected prog-
nostic associations with patient outcomes were observed
[37, 39]: Luminal A and Normal-like demonstrated better
outcomes, and Luminal B, Basal and Her2 had less favor-
able survival (Additional file 1: Figure S5). We found that
Table 2 Univariate and multivariate regression analysis of combined cohorts 1 and 2
Univariate Multivariateac (LN status excluded) Multivariatebc (LN status included)
Covariates Cox P value * HR 95% CI Cox P value * HR 95% CI Cox P value* HR 95% CI
DCYTB 1.11E-07 0.79 0.73–0.87 0.03 0.84 0.71–0.98 0.25 0.90 0.75–1.08
Size 0.41 1.00 0.99–1.01 0.02 1.01 1.00–1.02 0.05 1.01 0.99–1.02
Grade 2 1.20E-05 2.34 1.60–3.42 3.90E-03 2.07 1.26–3.38 0.01 1.97 1.17–3.34
Grade 3 2.53E-11 3.64 2.50–5.32 7.51E-04 2.53 1.48–4.35 0.01 2.29 1.27–4.15
ER status 4.14E-07 0.56 0.45–0.69 0.59 0.89 0.57–1.37 0.36 0.79 0.47–1.32
LN status 7.14E-05 1.53 1.24–1.89 - - - 0.01 1.55 1.09–2.21
LN lymph node, HR hazard ratio, CI confidence interval, DCYTB duodenal cytochrome b, ER estrogen receptor,
*Likelihood ratio test P value
a612 patients had complete clinical annotation for size, grade, age and ER status
b464 patients had complete clinical annotation for size, grade, ER and LN status
cER status was not significant in the multivariate analysis, possibly due to collinearity with grade in this dataset or to criteria used in assembling cohort #2 (in
particular, the requirement for a relatively high (>20%) event rate, which may have enriched for studies with fewer ER+/LumA tumors)
a b
c d
Fig. 2 DCYTB predicts outcome independent of ER and LN status. Kaplan-Meier analysis of patients in cohort #1 subsetted by high and low
DCYTB expression and a ER+ (p = 1.3e-10, n = 643), b ER- (p = 0.03, n = 89), c LN+ (p = 1.5e-07, n = 364), d LN- (p = 0.0001, n = 358). DCYTB
duodenal cytochrome b, ER estrogen receptor, LN lymph node
Lemler et al. Breast Cancer Research  (2017) 19:25 Page 5 of 18
DCYTB expression was higher in subtypes with more fa-
vorable prognoses (Fig. 3). Thus, Luminal A subtype had
significantly higher DCYTB expression than all other sub-
types (p ≤ 0.0028, pairwise t test). Similarly, Normal-like
subtype had significantly higher DCYTB expression than
all other subtypes with less favorable prognosis (p ≤ 2.8e-
15, pairwise t test). Basal subtype, which is associated with
a poorer breast cancer prognosis, had significantly
reduced DCYTB expression compared to all other sub-
types (p ≤ 0.0027, pairwise t test). Subtype information
was also available for a subset of patients from cohort #2
(Additional file 1: Figure S6a). Similar to what we ob-
served in cohort #1, cohort #2 patients with Luminal A
subtype had significantly more DCYTB expression com-
pared to Luminal B, Her2 and Basal subtypes and the
Normal-like subtype was significantly increased compared
to Luminal B and Basal (Additional file 1: Figure S6b).
Thus, high DCYTB expression is associated with subtypes
that have better outcome.
Expression of DCYTB is associated with response to therapy
Finally, we asked whether DCYTB expression was asso-
ciated with response to therapy. To address this ques-
tion, we first examined a subset of ER+, LN- patients
from cohort #1 that were histologically similar and had
been treated with tamoxifen monotherapy (n = 263) [32].
DCYTB expression identified patients with improved
DMFS in this group (p = 5.7e-05, log-rank test; Fig. 4a).
To determine whether DCYTB also separated patients
treated with chemotherapy, we examined a subset of co-
hort #2. This group consisted of 303 patients who were
ERBB2- (Her2-) and either ER+ or ER- and had been
treated with taxane-anthracycline neoadjuvant chemo-
therapy (and tamoxifen if ER+) followed by surgery
(GSE25055) [40]. We found that DCYTB identified
patients with improved RFS in this group (p = 0.003, log-
rank test, Fig. 4b). Thus DCYTB can identify subgroups
with different outcomes within homogeneously treated
patient groups who have received either chemotherapy
or hormone therapy.
DCYTB expression and localization in normal and
malignant breast tissue
We next investigated the level of DCYTB in normal and
malignant breast tissue. This analysis was restricted to
cohort #2 because only cohort #2 contained normal
breast samples. We observed that normal breast tissue
exhibited significantly higher levels of DCYTB mRNA
than malignant tissue (Additional file 1: Figure S7). Data
from the Cancer Genome Atlas (TCGA) representing
1100 tumors and 112 normal controls similarly revealed
an increase in DCYTB expression in normal breast
tissue (Additional file 1: Figure S7B).
a
b
Fig. 4 DCYTB predicts treatment outcome in tamoxifen and
chemotherapy-treated cohorts. a Kaplan-Meier analysis of ER+ patients in
cohort #1 who received tamoxifen monotherapy subsetted by high and
low DCYTB expression, p= 5.7e-05, n = 263, log-rank test. b Kaplan-Meier
analysis of patients who were ERBB2- (Her2-) and either ER+ or ER- and
had been treated with taxane-anthracycline neoadjuvant chemo-
therapy (and tamoxifen if ER+) followed by surgery (GSE25055)
[40], p = 0.003, n = 303, log-rank test. DCYTB duodenal
cytochrome b
Fig. 3 Increased DCYTB expression in molecular subtypes with better
outcome in cohort #1. DCYTB expression in each breast cancer
molecular subtype of cohort #1. Luminal A, n = 252; Normal-like,
n = 154; Luminal B, n = 136; Her2, n = 61; Basal, n = 104. *p ≤
0.0028 vs LumA, **p ≤ 2.8e-15 vs LumA and Normal-like cohorts,
***p ≤ 0.0027 vs all other cohorts. DCYTB duodenal cytochrome b
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We then assessed the cellular distribution and
localization of DCYTB in breast tissue using immuno-
histochemical analysis of a tissue microarray containing
75 breast cancer cases and nonmalignant controls. Our
first objective was to assess whether DCYTB was limited
to breast epithelial cells or was present in immune,
endothelial, adipose or other cell types that constitute
tumor tissue. We also expected to gain information on
the potential function of DCYTB by assessing its intra-
cellular distribution. In the duodenum, where DCYTB
functions in iron import, DCYTB is localized to the
brush border, on the surface of the enterocyte [16]. In
both esophageal carcinoma and in normal and malignant
colon, however, DCYTB is located in the membrane of
intracellular vesicles [41, 42]. Other members of the
cytochrome b561 family, which function in vesicular cat-
echolamine synthesis and lysosomal degradation, are
expressed in the membrane of intracellular organelles
[20, 43, 44].
We observed that DCYTB was present on the luminal
surface of epithelial cells in breast ducts and on the cell
membrane of myoepithelial cells in normal breast tissue
(Fig. 5a). Consistent with previous reports, erythrocyte
membranes also stained positive for DCYTB [23].
Cribriform-type ductal carcinoma in situ (DCIS) showed
intense staining along the luminal surfaces, similar to nor-
mal tissue, with additional faint cytoplasmic staining
(Fig. 5b). Invasive tumors displayed reduced gland/tubule
formation [45, 46], with a corresponding reduction in epi-
thelial cells with membrane expression of DCYTB (Fig. 5c).
Consistent with DCTYB mRNA levels, quantification of
immunohistochemical staining in breast epithelial cells
revealed that DCYTB protein was significantly reduced in
invasive ductal carcinoma breast cancers (n = 60) as
compared to normal adjacent breast epithelial tissue
(n = 3) (p = .019, Additional file 1: Figure S8).
In addition to its role in intestinal iron uptake, DYCTB





Fig. 5 Tissue expression of DCYTB and DMT1. Representative images of immunohistochemical staining of a breast tissue microarray (×20 magnification)
and de-identified duodenal tissue from UConn Health Center Department of Pathology. a, d Normal adjacent breast tissue; b, e cribriform-type DCIS ER/PR
+; c, f invasive ductal carcinoma, grade 3, triple negative; g, h normal human duodenum, ×40; i normal adjacent breast tissue, control
stained with secondary antibody only, ×40; j normal human duodenum, control stained with IgG instead of primary antibody, ×40. The box in the
series of images to the left, a-c and d-f, represent the location of the magnified image to the right. Scale bar = 20 μm. DCIS ductal carcinoma in situ,
DCYTB duodenal cytochrome b, DMT1 divalent metal transporter 1, ER estrogen receptor, PR progesterone receptor
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epithelial cells through a mechanism involving DCYTB-
mediated ferrireduction, uptake of divalent iron by diva-
lent metal transporter 1 (DMT1), and storage in ferritin
[22]. Since a role for DCYTB in either iron import or
detoxification requires DMT1, we performed immuno-
histochemical analysis of DMT1. As expected, in control
duodenal tissue, expression of DCYTB and DMT1 over-
lapped (Fig. 5g,h), consistent with the functional partner-
ship of DCYTB and DMT1 in iron reduction and
import in this tissue [16, 47]. In contrast, in the breast,
expression of DMT1 was predominantly cytoplasmic,
with minimal membrane staining (Fig. 5d-f ). Collect-
ively, these data suggest that DCYTB expressed in breast
tissue may not function in its typical iron import role.
Effects of DCYTB expression on iron metabolism in breast
cancer cells
To directly test whether DCYTB affects iron metabolism
in breast cells, we selected breast cell lines with high and
low expression of DCYTB. As shown in Additional file 1:
Figure S9, Western blot and qRT-PCR analysis indicated
that T47D ductal carcinoma cells exhibited high basal ex-
pression of DCYTB, whereas MCF7 breast cancer cells ex-
hibited substantially lower DCYTB expression.
To determine whether DCYTB played a role in iron
import in breast cancer cells, we overexpressed and
knocked down DCYTB and assessed effects on parame-
ters of iron metabolism. We first constitutively overex-
pressed DCYTB in MCF7 cells, which express low levels
of endogenous DCYTB (Fig. 6a). To confirm that this
exogenous DCYTB was functional, we measured its en-
zymatic activity using a ferrireductase assay. Tet-off
DCYTB-EGFP MDCK cells, which have been previously
shown to express doxycycline-regulated functional
DCYTB with ferrireductase activity [18], were used as a
control. As seen in Fig. 6b, MCF7 cells overexpressing
DCYTB had significantly higher ferrireductase activity
than cells transfected with empty vector. Control
DCYTB-EGFP MDCK cells exhibited the expected
doxycycline-regulated decline in ferrireductase activity
(Fig. 6b). Thus exogenous DCYTB is expressed and
functional in MCF7 cells.
We then tested whether DCYTB modulated iron im-
port by examining transferrin receptor 1 (TFRC) and
ferritin H (FTH1), two sensitive indicators of intracellu-
lar iron [48–50]. Expression of these proteins is post-
translationally regulated by iron: transferrin receptor
expression is increased in iron deplete conditions and
decreased in iron replete conditions, while the opposite
is true of ferritin H. Thus, high TFRC expression
coupled with low FTH1 is indicative of a state of de-
creased cellular iron, whereas low TFRC and high FTH1
indicates elevated levels of cellular iron. We observed no
difference in transferrin receptor or ferritin H expression
in MCF7 cells expressing DCYTB when compared to
cells infected with the empty vector (Fig. 6a), indicating
that exogenous DCYTB does not affect levels of intracel-
lular iron.
To further investigate the effects of DCYTB, we per-
formed the converse experiment by knocking down
a b
Fig. 6 Expression and activity of DCYTB in cultured breast cells does not affect iron metabolism. a Western blot of iron-responsive protein expres-
sion in constitutive DCYTB expressing MCF7 cells. Triplicate samples are shown. b FerroZine assay at pH 6.4 of indicated cells. Results are the
mean and standard deviation of triplicate samples. Similar results were obtained in at least three independent experiments. DCYTB duodenal
cytochrome b
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DCYTB in T47D cells, which express high levels of en-
dogenous DCYTB (Fig. 7a). DCYTB was significantly re-
duced by transfection of targeted siRNA (Fig. 7a);
however, ferritin H and transferrin receptor were not af-
fected. Consistent with these results, measurement of
the labile iron pool revealed no change in labile iron as a
function of DCYTB expression (Fig. 7b). To confirm
these results, we also assessed total cellular iron by in-
ductively coupled plasma-mass spectrometry (ICP-MS)
in DCYTB knockdown T47D cells and DCYTB-
overexpressing MCF7 cells. Treatment with iron was
used as a control. In both cell types, levels of intracellu-
lar iron were comparable, regardless of the level of
DCYTB expression (Fig. 8a,b). This suggests that modu-
lation of DCYTB expression does not significantly influ-
ence overall levels of cellular iron.
However, it remained possible that DCYTB might fa-
cilitate iron uptake under the specific condition of iron
excess. To explore this, we used T47D and MCF7 cells
expressing a Tet-inducible DCYTB expression vector,
which enabled us to modulate DCYTB expression over a
more graded range than that obtained using constitutive
overexpression (Additional file 1: Figure S10). We found
that in both T47D and MCF7 cells, basal levels of ferritin
H were unaffected by DCYTB expression, regardless of
the levels of DCYTB induction, supporting results ob-
tained with constitutive expression of DCYTB (Add-
itional file 1: Figure S10). We then compared the effect
of DCYTB on the response of cells to exogenous iron
(ferric ammonium citrate, FAC). In all cases, iron in-
duced ferritin H and increased the labile iron pool to a
similar extent (Fig. 9). Thus, in both T47D and MCF7
cells, there was an approximate three- to fourfold in-
crease in ferritin with 200 μM FAC, regardless of the
level of DCYTB (Fig. 9a and c). Similarly, labile iron in
both T47D and MCF7 cells was unchanged by DCYTB
expression (Fig. 9b,d). Consistent with these results,
ICP-MS analysis of cells cultured for 24 hours in
200 μM FAC revealed no effect of DCYTB status on
total cellular iron (Fig. 8a &b).
DYCB inhibits adhesion and the activity of focal adhesion
kinase
Although we observed that DCYTB was capable of redu-
cing iron (Fig. 6b), expression of DCYTB had no meas-
urable effect on iron levels in breast cancer cells (Figs. 6,
7, 8 and 9). We therefore sought to identify other mo-
lecular functions of DCYTB that might be responsible
for its positive association with prognosis. To accom-
plish this, we compared expression profiles from patients
that expressed the highest (≥90th percentile) and lowest
(≤10th percentile) levels of DCYTB in cohorts #1 and #2
and then used the Signaling Pathway Impact Analysis
(SPIA) package [51, 52] in the statistical software envir-
onment “R” [53] to discover pathways that might be af-
fected by DCYTB expression. We found that expression
of DCYTB was significantly associated with alterations
in the cell cycle, focal adhesion, extracellular matrix
(ECM)-receptor interaction and p53 signaling pathways
(Additional file 2: Table S1). To test these associations
experimentally, we first assessed the effect of knockdown
or overexpression of DCYTB on cell proliferation and
the cell cycle. We observed that the rate of increase in
cell number was the same in T47D cells treated with
siDCYTB or control siRNA, and was also unchanged in
MCF7 cells that overexpressed DCYTB when compared
to controls (Additional file 1: Figure S11a, b). Similarly,
there was no effect of DCYTB on progression through the
cell cycle in T47D cells treated with siGAPDH or siD-
CYTB (Additional file 1: Figure S12a, b). Thus, expression
a b
Fig. 7 Knockdown of DCYTB in T47D cells does not affect proteins of iron metabolism. a Western blot of T47D cells with siRNA-mediated knockdown
of DCYTB or GAPDH (control). Triplicate samples are shown. b Labile iron pool of DCYTB knockdown and control T47D cells. Results represent the
mean and standard deviation of at least 14 replicate samples. Similar results were obtained in at least three independent experiments. DCYTB duodenal
cytochrome b
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of DCYTB does not appear to directly affect cell cycle
progression or proliferation of breast cancer cells.
Given the association between DCYTB and the focal ad-
hesion pathway found in the SPIA analysis, we next tested
whether DCYTB affected focal adhesion kinase (FAK).
FAK is a protein tyrosine kinase that plays a central role in
regulating cell adhesion and motility, thereby promoting
tumor progression and metastasis [54, 55]. We tested
whether DCYTB affected FAK activation by measuring
phosphorylation of FAK at tyr-925, a site that regulates
focal adhesion turnover [56]. As seen in Fig. 10, MCF7
cells that expressed high levels of DCYTB exhibited sub-
stantially reduced FAK phosphorylation. Consistent with
these results, DCYTB also reduced phosphorylation of
paxillin, an adapter protein involved in maturation of focal
adhesions [55] (Fig. 10). To directly assess the effect of
DCYTB on adhesion, we measured the adherence of
breast cancer cells to the extracellular matrix protein fi-
bronectin. As seen in Fig. 10, DCYTB attenuated the abil-
ity of MCF7 cells to adhere to fibronectin. A reduction in
FAK and paxillin phosphorylation and a corresponding in-
hibition of adhesion were also observed in SKBR3 breast
cancer cells transfected with inducible DCYTB (Fig. 10).
Collectively, these results indicate that DCYTB inhibits
FAK activation and cell adhesion.
Discussion
DCYTB was identified as one of 16 genes comprising an
iron regulatory gene signature (IRGS) that is predictive
of breast cancer patient survival [32]. In the IRGS, high
expression of DCYTB was associated with improved dis-
tant metastasis-free survival. This was unexpected, be-
cause in the duodenum, DCYTB acts in conjunction
with DMT1 to promote iron uptake, and an extensive
literature links enhanced iron uptake with increased ra-
ther than decreased cancer risk [2–10]. Our results re-
solve this apparent paradox between the anticipated role
of DCYTB and its association with favorable prognosis
by revealing that in breast cancer cells, DCYTB does not
play a role in iron acquisition.
We used immunohistochemical analysis to confirm
the expression of DCYTB protein in breast tissue and to
assess its cellular and subcellular localization (Fig. 5).
We observed that DCYTB is present on the cell surface
of epithelial and myoepithelial cells, and is particularly
abundant at the luminal surface of ducts. DCYTB did
not co-localize with DMT1, the transport protein with
which DCYTB partners for uptake of iron, casting doubt
on a role for DCYTB in iron transport or detoxification
in breast cells (Fig. 5). We therefore used cell culture ex-
periments to directly test the ability of DCYTB to im-
pact iron metabolism in breast cancer cells.
Neither DCYTB overexpression nor DCYTB knock-
down altered parameters of iron metabolism in breast
cancer cells. Exogenously expressed DCYTB exhibited
ferrireductase activity (Fig. 6b), indicating that the func-
tion of the transfected gene was preserved. However,
basal levels of ferritin, an iron storage protein that is
translationally regulated by iron, and transferrin recep-
tor, an iron import protein that is posttranscriptionally
regulated by iron, were unchanged following either over-
expression of DCYTB in MCF7 cells (Fig. 6a) or knock-
down in T47D breast cancer cells (Fig. 7a). Further,
DCYTB overexpression did not affect the response of
cells to excess exogenous iron (Figs. 8, 9a–c), the intra-
cellular labile iron pool (Figs. 7b, 9b–d), or total cellular
iron (Fig. 8).
To explore alternative roles for DCYTB in breast can-
cer, we used Signaling Pathway Impact Analysis (SPIA)
as a discovery platform. We found that DCYTB exhib-
ited a profound effect on the focal adhesion pathway,
inhibiting phosphorylation of FAK, a kinase that regu-
lates cell adhesion and motility [54, 57] and is often ab-
errantly expressed in cancer [58, 59] (Fig. 10).
a
b
Fig. 8 DCYTB expression does not affect total cellular iron. a
ICP-MS analysis of total cellular iron in DCYTB knockdown T47D
cells and b constitutive DCYTB-expressing MCF7 cells. Cells
were either untreated or exposed to 200 μM ferric ammonium
citrate (FAC) in growth medium for 24 hours. Results represent
the mean and standard deviation of three replicates. DCYTB
duodenal cytochrome b
Lemler et al. Breast Cancer Research  (2017) 19:25 Page 10 of 18
Phosphorylation of paxillin, an adaptor protein involved
in maturation of focal adhesions, was similarly repressed
by DCYTB, as was adhesion itself (Fig. 10). FAK lies at
the center of a highly complex web of interacting pro-
teins and signaling pathways [54, 55]. A connection be-
tween DCYTB and focal adhesions has not been
previously observed, and further experiments will be re-
quired to elucidate the mechanism(s) by which DCYTB
influences this complex pathway.
Consistent with an inhibitory role of DCYTB on FAK
activation, analysis of two combined cohorts that to-
gether total 1610 breast cancer patients as well as the
GOBO cohort (n = 1379) revealed that high DCYTB ex-
pression was associated with longer distant metastasis-
free survival and longer relapse-free survival (both local
and distant) (Fig. 1, Additional file 1: Figure S3).
Breast cancer patients have been successfully classified
into outcome groups based on molecular profiling [37, 38],
and several platforms for patient classification have been
developed, including Oncotype Dx, Mammaprint, PAM50,
and EndoPredict [60, 61]. DCYTB is not included in these
currently available commercial and research-based classifica-
tion systems. However, we observed that DCYTB expression
increased in molecular subtypes with more favorable prog-
nosis (Fig. 3 and Additional file 1: Figure S5), demonstrating
that as a prognostic marker, DCYTB exhibits behavior that
mimics known molecular markers of breast cancer.
Although evaluating patient prognosis is helpful to
physicians and patients, predicting outcome of therapy
is equally critical to clinical decision-making, and re-
mains a challenge in breast cancer [60, 62, 63]. We
therefore measured the association between DCYTB ex-
pression and survival in homogeneously treated groups
of breast cancer patients [40, 64]. We used two cohorts:
the first was a cohort of women with ER+ tumors who
had been treated with tamoxifen monotherapy (Fig. 4a),
and the second was a population of women with ERRB2-
tumors treated with neoadjuvant chemotherapy (Fig. 4b).
We observed a significant association of DCYTB expres-
sion with DMFS and relapse. In both cohorts, patients
a b
dc
Fig. 9 Iron-responsive protein expression and cellular labile iron in response to DCYTB induction. a. Iron-responsive protein expression in
T47D cells induced with doxycycline for 72 hours. Transferrin receptor and ferritin expression quantified with Fiji ImageJ [83] and normalized
to uninduced cells containing vector alone. b Labile iron pool measurement of T47D cells induced with doxycycline for 72 hours and iron treated
for 24 hours. c. Iron-respnsive proein expression in MCF7 cells treated as in panel (a). d. Labile iron pool measurements in MCF7 cells treated
as in panel (b). Results represent the mean and standard deviation of at least 15 replicate samples. Similar results were obtained in at least three
independent experiments. DCYTB duodenal cytochrome b
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with low DCYTB expression were more likely to recur
than those with high DCYTB expression (Fig. 4a,b).
These results suggest that measurement of DCYTB ex-
pression may be useful in tailoring therapy: for example,
it could help guide a subset of ER+ patients to more ag-
gressive therapy, or alternatively, identify those for
whom the risks of chemotherapy are less warranted. Use
of gene expression to stratify breast cancer patients in
this fashion has recently shown substantial promise [65].
Conclusions
Our results demonstrate that DCYTB is a strongly asso-
ciated with breast cancer patient prognosis and distin-
guishes disease outcome in homogeneously treated
cohorts of breast cancer patients. Although DCYTB re-
duces iron and facilitates iron uptake in other tissues, in
the breast, DCYTB functions via an iron-independent
mechanism, attenuating activation of focal adhesion kin-
ase and reducing cell adhesion.
a c
b d
Fig. 10 DCYTB expression inhibits adhesion to fibronectin. a Phosphorylation of FAK and paxillin was evaluated by Western blot in MCF7 cells expressing
doxycycline-inducible DCYTB or control empty vector (EV). Quantification of staining intensity was performed using ImageJ. b Adhesion of MCF7 cells ex-
pressing DCYTB or control empty vector (EV) to fibronectin. c Phosphorylation of FAK and paxillin in SKBR3 cells expressing doxycycline-inducible DCYTB or
control empty vector (EV). d Adhesion of SKBR3 cells expressing DYCTB or control empty vector (EV) to fibronectin. Graphs represent means and standard
deviation of 16 replicates and are representative of three independent experiments. DCYTB duodenal cytochrome b
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Methods
Cell culture and reagents
Reagents were purchased from the following vendors: 17-β-
estradiol (Sigma-Aldrich, St, Louis, MO, USA, E2758),
Tamoxifen (4-hydroxy-(Z)) (EMD Millipore, Billerica, MA,
USA, 579002), FerroZine (3-(2-Pyridyl)-5,6-diphenyl-1,2,4-
triazine-p,p’-disulfonic acid monosodium salt hydrate)
(Sigma-Aldrich, 160601), ferric ammonium citrate (Sigma-
Aldrich, F5879), Doxycycline hyclate (Sigma-Aldrich, 9891),
FuGENE® HD Transfection Reagent (Promega, Madison,
WI, USA, E2311), hydroxyurea (Sigma-Aldrich, H8627).
T47D breast cancer cells were obtained from the American
Type Culture Collection (ATCC) and grown in RPMI-1640
basal medium containing 10% FBS at 37° in 5% CO2.
MCF7 breast cancer cells were obtained from the ATCC
and grown in EMEM containing 10% FBS and 10 U/ml in-
sulin. MCF10A cells were obtained from the ATCC and
cultured in MEGM containing MEGM Bulletkit™ with
100 ng/ml cholera toxin (Sigma-Aldrich, C8052). SK-BR-3
were purchased from ATCC and were grown in 10% FBS
in HyClone™ McCoy’s 5A Media (GE Healthcare Life Sci-
ences, Marlborough, MA, USA). MDCK cells were a gen-
erous gift of Dr. Andrew McKie and were cultured in
DMEM supplemented with 10% Tet-free FBS (Takara Bio
USA, Inc., Mountain View, CA, USA, 631106 or Fisher
Scientific, SH3007003T) and puromycin (1.0 ng/ml) [18].
All basal media were obtained from Lonza (Basel,
Switzerland). FBS was purchased from Gemini Bio-
Products (Broderick, CA, USA).
Construction and selection of cell lines with DCYTB
overexpression
Constitutive DCYTB expression vector
The DCYTB coding sequencing was amplified from cDNA
of U138MG cells and cloned into BamHI and XbaI sites of
the pSL2 vector, a lentiviral overexpression vector contain-
ing enhanced green fluorescent protein (EGFP) [66]. Clon-
ing primers were: DCYTB-F (5′ TCGGGATCCGCCAT
GGAGGGCTACTGGCGCT 3′) and DCYTB-R (5′
TAGTCTAGATCACATGGTAGATCTCTGCCCAG 3′).
Sequence comparison with the reference gene in the NCBI
database revealed that the cloned DCYTB cDNA was a
polymorphic variant (S266N, rs10455 [67]). To express
wild-type DCYTB, the mutation in the pSL2-DCYTB
(S266N) variant was rectified using site-directed mutagen-
esis. All vectors were confirmed by DNA sequencing.
Inducible DCYTB expression vector
The following primers were used to amplify human
DCYTB cDNA from pSL2-DCYTB plasmid: Forward (5′-
CCCTCGTAAAGAATTCGCCACCATGGCCATGGAG
GGCTACTGG-3′) and reverse (5′- GAGGTGGTC
TGGATCCTTACATGGTAGATCTCTGCCCAGCC-3′).
Primers contained restriction enzyme sites for EcoR1 and
BamH1 respectively. The PCR product of DCYTB
(861 bp) was digested with EcoR1 and BamH1 and
inserted between the EcoR1/BamH1 sites of the pLVX-
TetOne-Puro vector (Takara Bio USA, Inc., Mountain
View, CA, USA). Plasmids were purified and sequenced.
Cells were transfected using FuGENE® HD transfection re-
agent followed by 2 weeks of puromycin selection.
siRNA
All reagents were obtained from GE Dharmacon
(Lafayette, CO, USA) siDCYTB (D-17132-02 and D-
17132-03) and siGAPDH (D-001140-01) were used for
knockdown experiments. Transfections were performed
according to the manufacturer’s recommendations using
Dharmafect #1 (T-2001) transfection reagent.
Western blotting
For DCYTB analysis, non-reduced samples were used;
other samples were reduced. Cells were lysed in NP-40
lysis buffer (1% Nonidet P-40, 0.5% deoxycholate, and
0.1% SDS) in the presence of protease and phosphatase
inhibitors (Roche Diagnostics, Basel, Switzerland) and
proteins separated by SDS-PAGE. Western blots were
probed with antibodies to DCYTB (Sigma-Aldrich,
HPA014757), transferrin receptor (Thermo Fisher Scien-
tific, Waltham, MA, USA, 13-6890), ferritin H [68], β-
actin (Sigma-Aldrich, A3854), total FAK and P-FAK
(Y925) (Cell Signaling Technology, Inc., Danvers, MA,
USA, 13009 and 3284), phospho-paxillin (Cell Signaling
Technology cat #2541), and paxillin (Cell Signaling
Technology cat# 12065).
mRNA expression
qRT-PCR was performed essentially as described [69], ex-
cept that RNA was isolated and purified using the High
Pure RNA Isolation Kit (Roche Diagnostics) and RT-
qPCR was carried out using 2X SYBR® Green PCR Master
Mix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in a
ViiA7 cycler (Applied Biosystems, Inc., Foster City, CA,
USA). Primers for PCR were designed with IDT Primer-
Quest software (Integrated DNA Technologies, Inc., Cor-
alville, IA, USA): DCYTB forward 5′-TGCATACAG
TACATTCCCGCCAGA-3′, DCYTB reverse 5′-ATG-
GAACCTCTTGCTCCCTGTTCA-3′, ACTB forward 5′-
TTGCCGACAGGATGCAGAAGGA-3′, ACTB reverse
5′-AGGTGGACAGCGAGGCCAGGAT-3′. GREB1 primers
were as described in [70].
Immunohistochemistry
Breast tissue microarrays were obtained from US
Biomax, Inc., (Rockville, MD, USA). Antigen retrieval
was performed using 0.05% citraconic anhydride (Acros
Organics, Geel, Belgium) at pH 7.4 prior to immuno-
staining with a rabbit anti-DCYTB antibody (Sigma-
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Aldrich, HPA014757) or rabbit anti-DMT1 antibody
(Sigma-Aldrich, HPA032140). Antibody to DCYTB was vali-
dated by immunofluorescence of cells that expressed high
and low levels of DCYTB (Additional file 1: Figure S13).
Slides were counterstained with hematoxylin (Poly Scien-
tific R&D Corp., Bay Shore, NY, USA). Images were ac-
quired using a Zeiss Axio Scan Z1 (Carl Zeiss Microscopy
GmbH., Jena, Germany).To quantify DCYTB expression,
stained microarray images were analyzed with Fiji soft-
ware using reciprocal intensity as previously described
[71]. Briefly, diaminobenzidine (DAB) signal was isolated
from images by color deconvolution. Regions of interest
were drawn around epithelial tissue throughout the entire
tissue core. Mean DAB intensity/area was then measured
in the regions of interest (breast epithelia). Reciprocal in-
tensity (expressed in arbitrary units) was derived by sub-
tracting the maximum intensity value from measured
mean DAB intensity/area values.
Immunofluorescence
4 × 105 DCYTB or empty vector-expressing MCF7 cells
were plated in an eight-chamber slide (BD Falcon,
Franklin Lakes, NJ, USA). Cells were fixed with 4% para-
formaldehyde for 15 minutes at room temperature,
blocked with 5% BSA at room temperature for 2 hours,
and incubated with anti-DCYTB (Sigma-Aldrich cat#
HPA014757) antibody overnight at 4 °C. Alexa Fluor 555
conjugated anti-rabbit IgG secondary antibody was ap-
plied at 1:800 dilutions for 1 hour. Slides were mounted
with ProLong Gold anti-fade reagent (Invitrogen, Carls-
bad, CA, USA). Images were acquired using inverted mi-
croscopy (Zeiss Axio Vert.A1).
Measurement of the labile iron pool (LIP)
The labile iron pool was measured essentially as de-
scribed [72]. Briefly, cells were transfected with siRNA
or treated with doxycycline for 48 hours. Cells were then
transferred to 96-well plates and incubated for an add-
itional 24 hours in growth medium with or without
200 μM ferric ammonium citrate (Sigma-Aldrich, F5879)
for 4 or 24 hours prior to assay. Cells were washed, incu-
bated with 2 μM calcein acetoxymethyl ester (Life Tech-
nologies, Carlsbad, CA, USA, C1430) for 15 to 30 minutes
at 37 °C, washed with phenol-free EMEM, and 100 μM
starch-conjugated deferoxamine (DFO) was added (a gen-
erous gift of Biomedical Frontiers, Inc., Minneapolis, MN,
USA). Fluorescence was measured at 485 nm excitation
and 535 nm emission (BioTek Synergy 2, BioTek,
Winooski, VT, USA). Following stabilization of the
fluorescence signal, 10 μM salicylaldehyde isonicotinoyl
hydrazone (SIH) was added for several minutes until a
stable signal was obtained. The change in fluorescence
following the addition of SIH (ΔF) was used as a meas-
ure of the labile iron pool.
Cell cycle analysis
Cells were synchronized with a 24-hour treatment of
2.0 mM hydroxyurea. Following release from
synchronization, cells were removed from culture dishes
and washed several times in PBS containing FBS and
2.0 mM EDTA and fixed in 70% ethanol at 4 °C overnight.
Fixed cells were treated with RNase and stained with pro-
pidium iodide using FxCycle™ PI/RNase Staining Solution
(Thermo Fisher Scientific, F10797). Fluorescence intensity
was collected using a MACSQuant Analyzer (Miltenyi
Biotec GmbH., Bergisch Gladbach, Germany). ModFit
software (Verity Software House, Topsham, ME, USA)
was used to calculate cell cycle histograms.
Adhesion assay
MCF7 or SKBR3 cells containing empty vector or
doxycycline-inducible DCYTB were treated with 1 μg/ml
doxycycline for 72 hours, trypsinized, and 20,000 cells
were allowed to adhere to a 96-well plate that had been
coated with fibronectin (5 μg/ml). After 1.5 hours, cells
were labeled with calcein-AM (Invitrogen), non-adherent
cells were washed off, and adherent cells were quantified
by measuring calcein fluorescence. Each experiment was
repeated three times and 8–16 replicate wells were used
in each determination. Significant differences were deter-
mined using two-tailed unpaired Student’s t tests.
Microarray data sets
Cohort #1 was downloaded in October 2013 from Can-
cer Research [32] as a preprocessed file. Individuals with
missing data (event data was unavailable for 18 patients)
were excluded from the analysis. Cohort #2 was assem-
bled from existing databases. Criteria for Cohort #2 were
a median follow-up of greater than 2.5 years, greater
than 100 patients in the study, an event rate of greater
than 20% and gene expression analysis on the Affymetrix
(Santa Clara, CA, USA) U133 platform and an outcome
measure of recurrence-free survival. Four publicly
available breast cancer patient datasets met our criteria:
(i) 303 (Discovery, GSE25055) and 193 (Validation,
GSE25065) patients from a prospective study at M.D.
Anderson Cancer Center that identified a predictive sig-
nature of response to neoadjuvant chemotherapy [40];
(ii) a retrospective study of frozen tissue of 272 lymph
node-negative patients from Rotterdam, Netherlands
who did not receive systemic adjuvant or neoadjuvant
therapy (GSE2034) [73]; and (iii) 101 cancer and 14
normal patient samples from Dublin, Ireland resected
prior to hormone or chemotherapy (GSE42568) [74].
GSE25055 was downloaded April 2015 and GSE25065,
GSE2034 and GSE42568 datasets were downloaded May
2015 from the National Center for Biotechnology Infor-
mation Gene Expression Omnibus [75, 76] along with
clinical and follow-up data. Where possible, CEL files
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were downloaded, preprocessed and RMA normalized.
Surrogate variable analysis (SVA package) was used to
batch correct cohort #2 [77, 78]. Analysis of the GOBO
cohort was performed using online software (http://
co.bmc.lu.se/gobo). Multivariable regression analysis was
performed on patients for whom all variables were in-
cluded in the dataset. This restricted analysis to 612 out
of 1610 patients when comparing size, grade, age and ER
status, and 464 patients when the analysis included LN
status. A total of 571 patients were analyzed in the
GOBO cohort.
Statistical analysis
Analysis of microarray datasets was performed using R:
A language and environment for computing using the
affy [79], survival [80, 81], limma [82] and SPIA [51, 52]
packages. Data downloaded for cohort #1 was on the
Affymetrix U133A and B or U133plus2 platforms, on
which two probes for DCYTB are present. In this case,
the DCYTB probe with the highest absolute value of ex-
pression after normalization was used for downstream
analysis. All data for cohort #2 was on the Affymetrix
U133A platform, on which only one DCYTB probe is
present. Kaplan-Meier (KM) survival analysis was used
to determine distant metastasis-free survival (DMFS),
relapse-free survival (RFS) (both local and distant) and
bone-specific (RFS). Significance of KM plots was deter-
mined by the log-rank test. Cox proportional hazards re-
gression was used to determine prognostic value of
DCYTB when size, grade, age, ER status and LN status
were included in the model. We used the Signaling Path-
way Impact analysis (SPIA) algorithm [51, 52], imple-
mented in R, to identify significantly activated or inhibited
pathways [pFWER (family-wise error rate) < 0.05], using
information from KEGG pathway annotations and differ-
entially expressed genes (p < 0.05) between high and low
DCYTB-expressing groups. Significance in cell culture ex-
periments was assessed using two-tailed t tests, with p <
0.05 accepted as significant. Significance of DCYTB im-
munohistochemical staining was assessed using the
Mann-Whitney rank sum test since the data were not nor-
mally distributed (Shapiro-Wilk test).
ICP-MS
All containers used for sample digestion and preparation
were pretreated with trace metal grade HNO3 to remove
metal contaminations. Protein samples were digested in
100 μl HNO3 (trace metal grade, Fisher Scientific) in
polypropylene reagent tubes (Sarstedt, Nümbrecht,
Germany) in a heating block at 90 °C for 3 hours after
which 100 μl of 10 M H2O2 (trace metal grade, Fisher
Scientific) was added to the solution. The digested sam-
ple was further diluted to 2 ml total volume with 1%
HNO3 and stored in precleaned polypropylene tubes
until measurement. To ensure elemental recovery of
>90%, NIST reference material (freeze-dried, powdered
bovine liver, SRM 1577c) as well as the common elem-
ental standard mix (VHG Labs, Inc., Manchester, NH,
USA) were simultaneously digested by the same method.
To determine background contamination from the tubes
an empty tube was treated with 1 ml HNO3 and pre-
pared concomitantly with the samples.
Inductively coupled plasma-mass spectroscopy (ICP-
MS) analysis was performed using an Agilent 7700x
equipped with an ASX 250 autosampler (Agilent Tech-
nologies, Santa Clara, CA, USA). The system was oper-
ated at a radio frequency power of 1550 W, an argon
plasma gas flow rate of 15 L/min, Ar carrier gas flow
rate of 1.04 L/min. Elements were measured in kinetic
energy discrimination (KED) mode using He gas
(4.3 ml/min). Data were quantified using a 9-point (0,
0.5, 1, 2, 5, 10, 50, 100, 1000 ppb (ng/g)) calibration
curve with external standards for Mg, Mn, Fe, Cu, and
Zn. For each sample, data were acquired in triplicate
and averaged. A coefficient of variance was determined
from frequent measurements of a sample containing
10 ppb of all elements analyzed. An internal standard
(Sc, Ge, Bi) introduced with the sample was used to cor-
rect for detector fluctuation and to monitor plasma sta-
bility. Elemental recovery was evaluated by measuring
NIST reference material (water SRM 1643e) and found
to be >90% for all determined elements.
Additional files
Additional file 1: Supplemental Figures. Figure S1. DCYTB
expression is higher in ER+ than ER- patients. Figure S2. DCYTB
expression decreases with increased tumor grade. Figure S3. High
DCYTB expression is associated with increased distant metastasis-free sur-
vival and reduced hazard in the GOBO combined breast tumor dataset. Fig-
ure S4. DCYTB predicts outcome independent of ER and LN status. Figure
S5. Survival by molecular subtype in cohort #1. Figure S6. Increased DCYTB
expression in molecular subtypes with better outcome in cohort #2. Figure
S7. DCYTB expression is decreased in breast tumors. Figure S8. DCYTB protein
is decreased in malignant breast tissue. Figure S9. DCYTB is expressed at
higher levels in T47D cells than MCF7 cells. Figure S10. Induction and activity
of Tet-on DCYTB expression vector. Figure S11. Modulation of DCYTB expres-
sion does not affect proliferation of cancerous breast cells. Figure S12.
Knockdown of DCYTB expression does not affect progression through the
cell cycle. Figure S13. Immunofluorescence staining of DCYTB or empty
vector expressing MCF7 cells. (PPTX 4201 kb)
Additional file 2: Supplemental Table. Table S1. Perturbed pathways
identified by Signaling Pathway Impact Analysis (SPIA). (DOCX 15 kb)
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